医学临床研究
  2025年5月4日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2019, Vol. 36 Issue (10): 1898-1900    DOI: 10.3969/j.issn.1671-7171.2019.10.009
  论著 本期目录 | 过刊浏览 | 高级检索 |
普萘洛尔对血管瘤患儿血清VEGF及其受体VGFR1、VGFR2表达水平的影响
李蕾1, 梁巍1, 陈琛1, 张红鹏2
1. 河北省人民医院,河北 石家庄 050000;
2. 邯郸市第七医院,河北 邯郸 056000
Effect of Propranolol on the Expression of VEGF and its Receptors VGFR1/VEGFR2 in Serum of Children with Hemangioma
LI Lei, LIANG Wei, CHEN Chen,et al
Hebei general hospital, Shijiazhuang, hebei,050000,China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的】探讨普萘洛尔对血管瘤患儿血清血管内皮生长因子(VEGF)及其受体VGFR1、VGFR2表达水平的影响。【方法】选择2014年12月至2017年12月本院收治的48例血管瘤患儿,所有患儿给予普萘洛尔口服(3个月以下0.5 mg/kg,3~6个月1 mg/kg,6个月以上2 mg/kg,2次/日,共计3个月)。记录患儿治疗前及治疗3个月后静脉血VEGF及其受体VGFR1、VGFR2水平,以超声测量观察组治疗前及治疗3月后肿瘤体积并进行疗效评价。【结果】治疗一个疗程后,患儿血清中VEGF及其受体VGFR1、VGFR2蛋白水平和mRNA表达水平均显著低于治疗前,差异有统计学意义(P<0.05)。治疗后血管瘤体积为(0.29±0.09)cm3显著低于治疗前的(0.78±0.15)cm3,差异有统计学意义(P<0.05)。治疗后Achauer疗效评定法评估治疗效果,其中优20例,良15例,可7例,差6例,优良率为72.9%。【结论】普萘洛尔治疗血管瘤患儿临床效果较佳,其机制可能与下调血清VEGF及其受体VGFR1、VGFR2的表达水平有关。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李蕾
梁巍
陈琛
张红鹏
关键词 血管瘤普萘洛尔血管内皮生长因子A    
Abstract:【Objective】To investigate the effect of propranolol on the expression of VEGF and its receptorsVGFR1/VEGFR2 in serum of children with hemangioma. 【Methods】From December 2014 to December 2017, 48 children with hemangioma in our hospital were selected. All the children were given propranolol orally (0.5 mg/kg for less than 3 months, 1 mg/kg for 3~6 months, 2 mg/kg for more than 6 months, twice a day, a total of 3 months). The levels of VEGF and its receptors VGFR1/VEGFR2 , were recorded before and 3 months after treatment. The tumor volume of the observation group before and 3 months after treatment was measured by ultrasound and the curative effect was evaluated. 【Results】 After one course of treatment, the levels of VEGF and its receptor VGFR1/VEGFR2 protein and mRNA expression in serum were significantly lower than those before treatment (P<0.05). The volume of hemangioma after treatment was (0.29 ± 0.09) cm3, which was significantly lower than that before treatment (0.78 ± 0.15) cm3, the difference was statistically significant (P<0.05). After treatment, Achauer method was used to evaluate the therapeutic effect, including 20 excellent cases, 15 good cases, 7 fair cases and 6 poor cases. The excellent and good rate was 72.9%.【Conclusion】The clinical effect of propranolol is better in children with hemangioma. The mechanism may be related to the down-regulation of serum VEGF and its receptor VGFR1/VEGFR2 expression levels.
Key wordsHemangioma    Propranolol    Vascular Endothelial Growth Factor A
收稿日期: 2019-01-31     
PACS:  R725.4  
基金资助:河北省卫生厅青年科技课题(20100170)
引用本文:   
李蕾, 梁巍, 陈琛, 张红鹏. 普萘洛尔对血管瘤患儿血清VEGF及其受体VGFR1、VGFR2表达水平的影响[J]. 医学临床研究, 2019, 36(10): 1898-1900.
LI Lei, LIANG Wei, CHEN Chen,et al. Effect of Propranolol on the Expression of VEGF and its Receptors VGFR1/VEGFR2 in Serum of Children with Hemangioma. JOURNAL OF CLINICAL RESEARCH, 2019, 36(10): 1898-1900.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.10.009     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I10/1898
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn